23:37 , Dec 21, 2017 |  BC Extra  |  Preclinical News

New pathway could overcome resistance to TKIs in cancer

In a paper published in...
21:27 , Oct 26, 2017 |  BC Innovations  |  Tools & Techniques

Ripe for enhancement

Although still largely the purview of academics, technologies for mapping enhancers to the genes they control are rapidly gaining efficiency and promise to unlock a trove of new targets for drug developers. But companies will...
20:46 , Oct 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Nasopharyngeal cancer Cell culture and mouse studies identified inhibitors of CDK7 that could help treat nasopharyngeal cancer (NPC). A screen of 126 small molecules identified three known inhibitors CDK7 that inhibited proliferation of seven...
03:01 , May 6, 2017 |  BioCentury  |  Product Development

Finding gems in India

For Agios Pharmaceuticals Inc. , the decision to license molecules from Indian CRO Aurigene Discovery Technologies Ltd. was a special case intended to save time getting a new project off the ground, rather than part...
18:14 , May 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting BRD4 or CDK7 could help treat diffuse intrinsic pontine glioma (DIPG). In DIPG cells from eight patients, a bromodomain inhibitor tool compound or a CDK7...
15:59 , Apr 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Cell culture studies suggest inhibiting CDK7 could help treat ovarian cancer. In five human ovarian cancer cell lines, a CDK7 inhibitor tool compound decreased proliferation compared with vehicle. In three of the...
07:00 , Aug 18, 2016 |  BC Innovations  |  Translation in Brief

The CDK5 checkpoint

Despite the clinical success of checkpoint inhibitors, immuno-oncologists still have an incomplete understanding of how the receptors and their ligands prevent antitumor immunity. In a new study, Case Western Reserve University researchers found mechanistic data...
07:00 , Jul 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Homeobox C10 (HOXC10); cyclin dependent kinase 7 (CDK7)

Cancer INDICATION: Breast cancer Patient sample and cell culture studies suggest CDK7 inhibitors could help treat HOXC10-expressing, chemotherapy-resistant breast cancer. In breast cancer patients receiving chemotherapy, levels of HOXC10 mRNA were 10 times higher in...
01:30 , Jan 14, 2016 |  BC Extra  |  Financial News

Gene control play Syros raises $40M

Syros Pharmaceuticals Inc. (Watertown, Mass.) raised $40 million in a venture round led by Deerfield Management. Fellow new investor Casdin Capital also participated, as did existing investors Fidelity, WuXi Healthcare Ventures, Polaris Partners, Redmile Group,...
08:00 , Nov 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Cyclin dependent kinase 7 (CDK7)

Cancer INDICATION: Breast cancer In vitro and mouse studies suggest inhibiting CDK7 could help treat triple-negative breast cancer (TNBC). In multiple human TNBC cell lines, the CDK7 inhibitor THZ1 decreased proliferation and expression of CDK7...